In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Perspective Therapeutics, with a price target of $5.00. The company’s shares closed yesterday at $4.83.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stranahan covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Agios Pharma, and Novavax. According to TipRanks, Stranahan has an average return of 1.4% and a 54.33% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Perspective Therapeutics with a $13.50 average price target.
The company has a one-year high of $13.19 and a one-year low of $1.60. Currently, Perspective Therapeutics has an average volume of 852.7K.
Read More on CATX:
Disclaimer & DisclosureReport an Issue
- Perspective Therapeutics initiated with a Buy at BTIG
- Positive Buy Rating for Perspective Therapeutics Driven by Promising Clinical Progress and Market Potential of FAP-Targeted Therapy
- Perspective Therapeutics announces first patient treated with PSV359
- Perspective Therapeutics Updates Radiopharmaceutical Advancements
- Optimistic Buy Rating for Perspective Therapeutics Driven by Promising Trial Results and Upcoming Catalysts
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
